What was Danaher's revenue in Q2 2026?

Danaher's revenue was $6.27 billion, up 5.5% year over year.

Did Danaher beat earnings estimates?

Yes, non-GAAP EPS of $1.94 beat estimates by 4.9%.

Danaher (DHR) Q2 2026 Revenue Beats Estimates, Stock Drops

Q: Why did DHR stock drop despite positive results?

Despite the beat, the decline may reflect investor concerns about high valuations or future growth prospects.

Danaher (NYSE: DHR) reported Q2 2026 results that exceeded revenue expectations, with sales rising 5.5% year over year to $6.27 billion. Non-GAAP earnings per share of $1.94 were 4.9% above analyst consensus. However, the stock declined in after-hours trading.

Danaher Corporation (NYSE: DHR) reported its Q2 2026 financial results, surpassing market revenue expectations. Revenue reached $6.27 billion, up 5.5% year over year. Non-GAAP earnings per share came in at $1.94, beating analyst estimates by 4.9%. Despite the positive results, DHR shares dropped in trading.

Key Financial Results

Metric	Q2 2026	Q2 2025	YoY Change
Revenue	$6.27B	$5.94B	+5.5%
Non-GAAP EPS	$1.94	—	—

Note: The company did not disclose net income or prior-year EPS comparison.

Highlights from the Report

Danaher attributed revenue growth to strong performance across its key segments, particularly in life sciences and diagnostics. However, no further details were provided on growth drivers.

Guidance

Danaher did not issue formal guidance for the next quarter or full fiscal year 2026 in this release.

Impact on the Stock

Despite beating estimates, DHR shares declined in subsequent trading. This may reflect investor concerns about high valuations, future growth prospects, or broader macroeconomic factors.

What This Means for Investors

Danaher's revenue and earnings beat indicates continued demand for its products in the science and diagnostics sectors. However, the stock drop serves as a reminder that single-quarter results do not always dictate long-term trends, and market sentiment can override fundamental performance.